1. [Dermatomyositis with squamous cell carcinoma of the lungs secondary to nivolumab treatment: a case report].
- Author
-
Miyashita K, Kajikawa H, Utsunomiya T, Hosaka M, Naito Y, and Tomimoto H
- Subjects
- Aged, Autoantibodies, Dermatomyositis diagnosis, Dermatomyositis therapy, Fatal Outcome, Humans, Immunoglobulins, Intravenous therapeutic use, Immunotherapy, Male, Methylprednisolone administration & dosage, Pulse Therapy, Drug, Tacrolimus therapeutic use, Transcription Factors immunology, Antineoplastic Agents, Immunological adverse effects, Antineoplastic Agents, Immunological therapeutic use, Carcinoma, Squamous Cell drug therapy, Dermatomyositis chemically induced, Immune Checkpoint Inhibitors adverse effects, Immune Checkpoint Inhibitors therapeutic use, Lung Neoplasms drug therapy, Nivolumab adverse effects, Nivolumab therapeutic use
- Abstract
A 74-year-old man was administered nivolumab to treat recurrent squamous cell carcinoma of the lungs. He developed fatigue, redness on the front of his neck, muscle weakness, and difficulty in swallowing after receiving the third course of nivolumab. Physical and neurological examinations showed proximal limb muscle weakness, periorbital erythema, and erythema of the front of his neck as well as fingers. Laboratory investigations revealed elevated serum CK and aldolase levels, and he was diagnosed with dermatomyositis. We initiated steroid pulse therapy and intravenous immunoglobulin therapy; however, he died of advanced lung cancer. Immune checkpoint inhibitor-induced neuromuscular disease is increasingly being observed in clinical practice. We report a rare case of dermatomyositis with squamous cell carcinoma of the lungs secondary to nivolumab treatment.
- Published
- 2020
- Full Text
- View/download PDF